A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Aligos Therapeutics Inc’s current trading price is 0.98% away from its 52-week high, while its distance from the 52-week low is 541.57%. The stock’s price range for this time frame has been between $6.76 and $42.95. The trading volume of the company’s shares in the Healthcare reached around 0.79 million for the day, which was evidently higher than the average daily volume of 0.35 million over the last three months.
The market performance of Aligos Therapeutics Inc has been somewhat stable. Over the past year, the company’s stock achieved a high of $42.95 on 12/26/24, with the lowest value for the same timeframe being $6.76, recorded on 10/08/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Aligos Therapeutics Inc (ALGS) has experienced a quarterly rise of 440.77% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 155.61M and boasts a workforce of 66 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 16.03, with a change in price of +31.88. Similarly, Aligos Therapeutics Inc recorded 265,342 in trading volume during the last 100 days, posting a change of +277.29%.
How ALGS’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for ALGS stands at 0.18. Similarly, the long-term debt-to-equity ratio is also 0.11.
ALGS Stock Stochastic Average
Aligos Therapeutics Inc’s raw stochastic average for the past 50 days is currently at 98.45%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 97.46%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 88.90% and 86.41%, respectively.
ALGS Stock Price Performance Analysis
The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price increase of 161.27%. However, over the past six months, we’ve seen a weaker performance of 358.46%. The price of ALGS fallen by 111.97% over the last 30 days. And in the last five days, it has surged by 31.38%.
